Related references
Note: Only part of the references are listed.Oral disease-modifying therapies for multiple sclerosis in the Middle Eastern and North African (MENA) region: an overview
Dirk Deleu et al.
CURRENT MEDICAL RESEARCH AND OPINION (2019)
Comparative effectiveness of teriflunomide and dimethyl fumarate A nationwide cohort study
Mathias Due Buron et al.
NEUROLOGY (2019)
Effectiveness of oral multiple sclerosis therapies in clinical context
Tomas Kalincik
NEUROLOGY (2019)
Harnessing real-world data to inform treatment decisions in multiple sclerosis
Carrie M. Hersh et al.
NEUROLOGY (2019)
Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
David-Axel Laplaud et al.
NEUROLOGY (2019)
Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience
E. D'Amico et al.
JOURNAL OF NEUROLOGY (2019)
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
Tomas Kalincik et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)
The Akaike information criterion: Background, derivation, properties, application, interpretation, and refinements
Joseph E. Cavanaugh et al.
WILEY INTERDISCIPLINARY REVIEWS-COMPUTATIONAL STATISTICS (2019)
Multiple Sclerosis
Daniel S. Reich et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience
Emanuele D'Amico et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2018)
Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database
Aaron Boster et al.
NEUROLOGY AND THERAPY (2017)
Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis
Jens Ingwersen et al.
NEUROTHERAPEUTICS (2016)
Long-term safety and efficacy of teriflunomide Nine-year follow-up of the randomized TEMSO study
Paul O'Connor et al.
NEUROLOGY (2016)
Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis
Mark S. Freedman et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)
Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal
Emanuele D'Amico et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2015)
Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal
Emanuele D'Amico et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2015)
Missing data in longitudinal studies: cross-sectional multiple imputation provides similar estimates to full-information maximum likelihood
Mark A. Ferro
ANNALS OF EPIDEMIOLOGY (2014)
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
Christian Confavreux et al.
LANCET NEUROLOGY (2014)
Practical considerations for sensitivity analysis after multiple imputation applied to epidemiological studies with incomplete data
Vanina Heraud-Bousquet et al.
BMC MEDICAL RESEARCH METHODOLOGY (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Robert J. Fox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Ralf Gold et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Improved AIC selection strategy for survival analysis
Hua Liang et al.
COMPUTATIONAL STATISTICS & DATA ANALYSIS (2008)
Sensitivity analysis after multiple imputation under missing at random: a weighting approach
James R. Carpenter et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2007)
Share Paper
